CTOs on the Move

TearClear

www.tearclear.com

 
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

TearClear raised $22M on 08/11/2020

Similar Companies

Vitacorp International Inc

Vitacorp International Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DynPort Vaccine Company

DynPort Vaccine Company LLC (DVC) provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement,

Medsite

Medsite is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Robinson Pharma

Since 1989 Robinson Pharma, Inc. (RPI) has served domestic and international marketers of vitamins and dietary supplements. From its humble beginnings as a contract packager, RPI has grown to become a significant entity in the dietary supplement industry

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.